Coronavirus Update: Bharat's Vaccine Looks Good In New Analysis
Plus: Serum Sets India Price, RDIF Inks Korea Deal
New Phase III data show efficacy ranging up to 100% for Bharat Biotech's inactivated vaccine, while also in India, Serum Institute sets new prices for its vaccine. Meanwhile, Russia's RDIF strikes new production deals in South Korea.
You may also be interested in...
Brazil is permitting imports of additional coronavirus vaccines, while in India, Serum Institute will manufacture Sputnik V, the government is unifying vaccine sourcing, and emergency use approval has been granted to Lilly's anti-COVID-19 antibodies.
Prices for J&J and Pfizer’s COVID-19 vaccines will be watched closely as India permits private sales. While demand is set to spike with age criteria for those eligible to receive the shots expanded, local manufacturers Serum Institute and Bharat Biotech are ramping up capacities with the government’s help.
India clears Russian vaccine for restricted use, adding a third vaccine to its arsenal in the fight against COVID-19. One local expert highlights the vaccine’s “clever design” amid hopes that it will hold good against variants as well.